GLP-1 Coverage & Costs in New Jersey (2026)
$79/month (Embody, compounded semaglutide, monthly plan) is the lowest monthly-plan price we have recorded among the programs on this page. Embody lists 48 states and our records do not name them, so confirm New Jersey at intake.
The lowest recorded compounded tirzepatide price is $129/month (Embody, monthly plan). Among programs recorded as available in all 50 states, the lowest is $139/month (AgelessRx, compounded semaglutide, monthly plan). 6 of the 49 programs listed have no recorded price. Recorded prices cover medication and known program fees, not a verified total.
New Jersey Medicaid Coverage for GLP-1
Medicaid: not covered as of January 2026 (KFF)
KFF's map lists New Jersey as not covering GLP-1s for obesity under fee-for-service as of January 2026. Rules and later changes are not on that map, so confirm with the state Medicaid agency or your plan.
- Source: KFF, Medicaid Coverage of and Spending on GLP-1s, Figure 1 (January 16, 2026). Read 2026-11-06.
Your Options in New Jersey:
- Telehealth programs: recorded compounded prices from $79/month on a monthly plan, where the program serves New Jersey
- Commercial or employer insurance: check your plan's drug list and prior authorization rules
- Medicare GLP-1 Bridge for eligible Part D enrollees (see below)
New Jersey Medicaid GLP-1 Prescriptions in 2025
165,515
#18
$148.5 million
Ozempic
New Jersey Medicaid paid for 165,515 GLP-1 prescriptions in 2025, 1.5% of the 11.26 million paid nationally and number 18 of 51 (50 states and DC). It reimbursed pharmacies $148.5 million before manufacturer rebates, about $897 per prescription, and the most-filled product was Ozempic. These counts include diabetes prescriptions, not only weight loss. Wegovy, Zepbound and Saxenda, the brands approved for chronic weight management, made up 10,214 of those prescriptions (6.2%). Wegovy and Zepbound also carry other approved uses, so this is an upper bound on weight-loss use, not a count of it.
From 2021 to 2025, New Jersey Medicaid GLP-1 prescriptions went from 72,307 to 165,515, 2.3 times the 2021 count. From 2024 to 2025 the count rose by 28,890.
72,307
98,016
122,507
136,625
165,515
| Product | NJ Medicaid prescriptions, 2025 | Share |
|---|---|---|
| Ozempic | 64,809 | 39.2% |
| Mounjaro | 37,880 | 22.9% |
| Liraglutide (generic) | 30,995 | 18.7% |
| Trulicity | 12,746 | 7.7% |
| Zepbound | 6,385 | 3.9% |
| Bydureon | 6,107 | 3.7% |
| Wegovy | 3,829 | 2.3% |
| Rybelsus | 2,764 | 1.7% |
Source: CMS State Drug Utilization Data, 2025 (updated July 13, 2026), fee-for-service and managed care, all four quarters, compiled in our network's PriceTracker GLP-1 state table (read October 4, 2026); 2021 to 2024 summed by us from CMS's own yearly datasets with the same method, read November 9, 2026. CMS hides rows under 11 prescriptions, so small counts are slightly low. CMS publishes no per-enrollee rate here, so a total reflects the size of the program as much as use.
New Jersey Employee Plan and Insurer GLP-1 Rules
New Jersey State Health Benefits Program (SHBP)
Covers GLP-1s for weight lossNew Jersey's State Health Benefits Program covers Wegovy, Saxenda and Zepbound for weight loss in 2026, at a $45 copay for a 30-day retail supply or $135 for a 90-day mail-order supply.
The 2026 active-employee prescription plan design sets the copay for weight-loss GLP-1s.
“Effective January 1, 2026, GLP-1 weight loss drugs Wegovy, Saxenda, and Zepbound have a $45 copayment for a 30-day retail supply and a $135 copayment for a 90-day mail-order supply.”
Source: New Jersey Division of Pensions and Benefits. Read October 29, 2026.
We have no New Jerseyinsurer policy on record yet. Most commercial plans decide GLP-1 coverage plan by plan, so the employer's choice matters as much as the insurer.
Comparing self-pay programs in New Jersey?
2-minute quiz: filter by budget and medication preference.
Telehealth Programs to Check for New Jersey
We list 49 programs here. 21 are recorded as available in all 50 states. 7 more publish their own state list, summarized below for New Jersey. The rest record a state count without naming the states, so confirm New Jersey with the program at intake before you pay.
What Programs' Own Pages Say About New Jersey
8 of the 8 programs whose own pages name the states they serve include New Jersey: Willow, SnagRx, Strut Health, MangoRx, Wellorithm, MEDGm, TelosRx, Trimi. Pages read November 9, 2026. This is what each seller states about availability, not a licensing check.
| Program | New Jersey |
|---|---|
| Willow | Serves NJ |
| SnagRx | Serves NJ |
| Strut Health | Ships to NJ |
| MangoRx | Ships to NJ |
| Wellorithm | Serves NJ |
| MEDGm | Serves NJ |
| TelosRx | Serves NJ |
| Trimi | Serves NJ |
Trimi's state table lists New Jersey as served through the Arora Health network. Visit format there: Online evaluation through the Arora Health network. The telehealth law it cites for New Jersey is N.J.S.A. 45:1-62 (as amended by P.L.2026, c.40) and 45:1-63. That citation is Trimi's, not our legal reading. Trimi state table, read November 9, 2026.
Programs on Our List, in Published Order
Compounded GLP-1 care with one-month and prepaid plans
Personalized GLP-1 consultations with tailored prescriptions and ongoing physician support
Affordable compounded semaglutide from $119/mo with free shipping and health coaching
Personalized GLP-1 weight loss with licensed providers and nationwide coverage
45 more programs on our list: 19 recorded as available in all 50 states, 7 with a state list shown in the table above, and 19 with a state count but no published list we have read. Compare all of them side by side.
Estimated GLP-1 Costs in New Jersey
Telehealth (Compounded)
$79 to $399/moRecorded monthly-plan prices for compounded semaglutide and tirzepatide. Availability varies by program, so confirm your state at intake.
Wegovy
Brand prices with and without insurance.
Zepbound
List, LillyDirect and savings card prices.
No insurance
Self-pay GLP-1 options without coverage.
The compounded range is our recorded monthly-plan prices, the same in every state. Brand and insurance costs depend on the plan, so we link the pages that carry their sources. Compounded medications are not FDA-approved.
Medicare Part D GLP-1 Claims in New Jersey, 2024
New Jersey prescribers wrote 503,609 Medicare Part D GLP-1 claims in 2024, number 15 of 51, with $679.2 million in gross drug cost before rebates. Ozempic led with 236,628 claims for 47,299 enrollees. Wegovy had 7,847 claims. Part D did not pay for weight loss alone in 2024, so these fills are for diabetes and other approved uses.
| Product | NJ Part D claims | Enrollees |
|---|---|---|
| Ozempic | 236,628 | 47,299 |
| Mounjaro | 123,299 | 22,843 |
| Trulicity | 81,322 | 16,271 |
| Rybelsus | 34,650 | 8,811 |
| Bydureon Bcise | 12,815 | 2,709 |
| Wegovy | 7,847 | 1,928 |
| Victoza | 5,460 | Not given |
| Liraglutide | 1,087 | 432 |
| Byetta | 487 | 130 |
| Zepbound | 14 | 14 |
Source: CMS Medicare Part D Prescribers by Geography and Drug, 2024 (updated May 21, 2026), state rows, read November 9, 2026. The state is the prescriber's. Claims include refills, and enrollees are not added across products because one person can fill two.
Medicare GLP-1 Bridge Program in New Jersey
The Bridge is national, so the rules are the same in New Jersey as everywhere: eligible Part D enrollees pay $50/month for Foundayo, Wegovy or Zepbound KwikPen, subject to BMI rules and exclusions. Medicare fact sheet.
$50/mo
July 1, 2026
Dec 31, 2027
How New Jersey Compares to Other Northeast States
Medicaid coverage of GLP-1s for obesity is optional for states, so the answer differs by state. Here is how New Jersey and its neighbors in the Northeast are recorded:
| State | Medicaid and GLP-1s for obesity | Medicaid GLP-1 Rx, 2025 |
|---|---|---|
| New Jersey (this page) | Not covered | 165,515 |
| Connecticut | Not covered | 174,430 |
| Massachusetts | Not covered | 399,014 |
| New York | Not covered | 815,882 |
| Pennsylvania | Not covered | 843,743 |
Our recorded telehealth prices are not state-specific: $79 to $399/month on monthly plans. Medicaid and marketplace coverage is what varies.
KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026. Managed care plans may differ. Later counts may be lower: The RX Index, an independent tracker, listed 11 in a July 10, 2026 snapshot and says that is not a current national count. Sources read November 6, 2026. Policies change, so confirm with your state Medicaid agency or plan.
If Your Insurance Denies GLP-1 Coverage in New Jersey
Commercial plans offer an internal appeal, then external review; New Jersey Medicaid enrollees can ask for a fair hearing. The denial letter names the deadlines.
How to Check Your Specific Plan in New Jersey
- New Jersey Medicaid: Medicaid: not covered as of January 2026 (KFF). Ask your Medicaid plan for its drug list and prior authorization rules, or find the state agency on Medicaid.gov's state contacts.
- State employees: New Jersey State Health Benefits Program (SHBP), covers glp-1s for weight loss per the documents cited above. Confirm with the plan before you fill a prescription.
- Any other plan: call the number on your card and ask whether Wegovy or Zepbound is covered for weight loss, which tier it sits on, and what prior authorization needs. Get the answer in writing.
Find the Right GLP-1 Provider in New Jersey
Answer a few questions and we'll match you with the best GLP-1 program for your budget, insurance, and goals in New Jersey.
Frequently Asked Questions — New Jersey
Does New Jersey Medicaid cover GLP-1 medications for weight loss?
How many GLP-1 prescriptions did New Jersey Medicaid pay for in 2025?
How many Medicare Part D GLP-1 claims were there in New Jersey in 2024?
Does the New Jersey state employee health plan cover GLP-1s for weight loss?
What is the cheapest way to get GLP-1 medication in New Jersey?
Which online GLP-1 programs serve New Jersey?
Does Medicare cover GLP-1s in New Jersey?
Ready to start?
Compare the recorded costs, sources and evidence gaps for 52 listed providers. Confirm current terms with the provider before enrolling.